Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2017 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.1%

Alnylam Pharmaceuticals reported a smaller-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 1.1% in reaction, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future prospects without further clarity on performance metrics.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.07	N/A	+10.46%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a sense of cautious optimism regarding their clinical advancements. They acknowledged the competitive landscape but emphasized their commitment to innovation.

Management highlighted progress in ongoing clinical trials.

They expressed confidence in their pipeline but noted challenges ahead.

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.1%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.1%

Key numbers

Management commentary